Ventripoint Diagnostics Ltd. announced that it has filed an application with Health Canada for approval of the expansion of the VMS(TM) heart analysis product to include right atrium (RA), left atrium (LA) and left ventricle (LV) chambers of the heart. The VMS is already licensed in Canada for use for the right ventricle (RV). This expansion allows the determination of volume and function for all four chambers of the heart using conventional 2D ultrasound and reduces the need for costly and delayed MRI exams, which is the only other way to get accurate and reliable measurements. The company have successfully built and tested the KBR databases for the RA, LA and LV to yield results substantially equivalent to gold-standard MRI, stated Dr. George Adams, CEO of Ventripoint. This will enable patients to be fully evaluated using 2D ultrasound on each visit and allow for better monitoring of changes in the anatomy and function of the heart. Health Canada usually approves such applications in 30 to 60 days and the company will begin marketing the product as soon as it receives the medical device license to do so in Canada.